|
1
|
Nasim F, Sabath BF and Eapen GA: Lung
cancer. Med Clin North Am. 103:463–473. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li C, Lei S, Ding L, Xu Y, Wu X, Wang H,
Zhang Z, Gao T, Zhang Y and Li L: Global burden and trends of lung
cancer incidence and mortality. Chin Med J (Engl). 136:1583–1590.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Doherty GJ and McMahon HT: Mechanisms of
endocytosis. Annu Rev Biochem. 78:857–902. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lanzetti L and Di Fiore PP: Endocytosis
and cancer: An ‘insider’ network with dangerous liaisons. Traffic.
9:2011–2021. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Théry C, Ostrowski M and Segura E:
Membrane vesicles as conveyors of immune responses. Nat Rev
Immunol. 9:581–593. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen PH, Bendris N, Hsiao YJ, Reis CR,
Mettlen M, Chen HY, Yu SL and Schmid SL: Crosstalk between
CLCb/Dyn1-mediated adaptive clathrin-mediated endocytosis and
epidermal growth factor receptor signaling increases metastasis.
Dev Cell. 40:278–288.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ketteler J and Klein D: Caveolin-1, cancer
and therapy resistance. Int J Cancer. 143:2092–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roy S, Wyse B and Hancock JF: H-Ras
signaling and K-Ras signaling are differentially dependent on
endocytosis. Mol Cell Biol. 22:5128–5140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim B, Park YS, Sung JS, Lee JW, Lee SB
and Kim YH: Clathrin-mediated EGFR endocytosis as a potential
therapeutic strategy for overcoming primary resistance of EGFR TKI
in wild-type EGFR non-small cell lung cancer. Cancer Med.
10:372–385. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao GY, Mohanakrishnan A and Schmid SL:
Role for ERK1/2-dependent activation of FCHSD2 in cancer
cell-selective regulation of clathrin-mediated endocytosis. Proc
Natl Acad Sci USA. 115:E9570–E9579. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jo U, Park KH, Whang YM, Sung JS, Won NH,
Park JK and Kim YH: EGFR endocytosis is a novel therapeutic target
in lung cancer with wild-type EGFR. Oncotarget. 5:1265–1278. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nishimura Y, Bereczky B and Ono M: The
EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis
of EGFR via the early/late endocytic pathway in non-small cell lung
cancer cell lines. Histochem Cell Biol. 127:541–553. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishimura Y, Yoshioka K, Bereczky B and
Itoh K: Evidence for efficient phosphorylation of EGFR and rapid
endocytosis of phosphorylated EGFR via the early/late endocytic
pathway in a gefitinib-sensitive non-small cell lung cancer cell
line. Mol Cancer. 7:422008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanaka T, Ozawa T, Oga E, Muraguchi A and
Sakurai H: Cisplatin-induced non-canonical endocytosis of EGFR via
p38 phosphorylation of the C-terminal region containing Ser-1015 in
non-small cell lung cancer cells. Oncol Lett. 15:9251–9256.
2018.PubMed/NCBI
|
|
19
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park JV, Chandra R, Cai L, Ganguly D, Li
H, Toombs JE, Girard L, Brekken RA and Minna JD: Tumor cells
modulate macrophage phenotype in a novel in vitro co-culture model
of the NSCLC tumor microenvironment. J Thorac Oncol. 17:1178–1191.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park JE, Dutta B, Tse SW, Gupta N, Tan CF,
Low JK, Yeoh KW, Kon OL, Tam JP and Sze SK: Hypoxia-induced tumor
exosomes promote M2-like macrophage polarization of infiltrating
myeloid cells and microRNA-mediated metabolic shift. Oncogene.
38:5158–5173. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tripathy S, Dassarma B, Roy S, Chabalala H
and Matsabisa MG: A review on possible modes of action of
chloroquine/hydroxychloroquine: Repurposing against SAR-CoV-2
(COVID-19) pandemic. Int J Antimicrob Agents. 56:1060282020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Johannes L and Billet A: Glycosylation and
raft endocytosis in cancer. Cancer Metastasis Rev. 39:375–396.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cooper ST and McNeil PL: Membrane repair:
Mechanisms and pathophysiology. Physiol Rev. 95:1205–1240. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao Y, Rabien A, Buschow R, Amtislavskiy
V, Busch J, Kilic E, Villegas SL, Timmermann B, Schütte M, Mielke
T, et al: Endocytosis-mediated replenishment of amino acids favors
cancer cell proliferation and survival in chromophobe renal cell
carcinoma. Cancer Res. 80:5491–5501. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Azad T, Rezaei R, Surendran A, Singaravelu
R, Boulton S, Dave J, Bell JC and Ilkow CS: Hippo signaling pathway
as a central mediator of receptors tyrosine kinases (RTKs) in
tumorigenesis. Cancers (Basel). 12:20422020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Du Z and Lovly CM: Mechanisms of receptor
tyrosine kinase activation in cancer. Mol Cancer. 17:582018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
da Cunha Santos G, Shepherd FA and Tsao
MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sim EH, Yang IA, Wood-Baker R, Bowman RV
and Fong KM: Gefitinib for advanced non-small cell lung cancer.
Cochrane Database Syst Rev. 1:CD0068472018.PubMed/NCBI
|
|
32
|
Sartori G, Belluomini L, Lombardo F,
Avancini A, Trestini I, Vita E, Tregnago D, Menis J, Bria E,
Milella M and Pilotto S: Efficacy and safety of afatinib for
non-small-cell lung cancer: State-of-the-art and future
perspectives. Expert Rev Anticancer Ther. 20:531–542. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Remon J, Steuer CE, Ramalingam SS and
Felip E: Osimertinib and other third-generation EGFR TKI in
EGFR-mutant NSCLC patients. Ann Oncol. 29 (Suppl 1):i20–i27. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu SG and Shih JY: Management of acquired
resistance to EGFR TKI-targeted therapy in advanced non-small cell
lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cruz Da Silva E, Choulier L,
Thevenard-Devy J, Schneider C, Carl P, Ronde P, Dedieu S and
Lehmann M: Role of endocytosis proteins in gefitinib-mediated EGFR
internalisation in glioma cells. Cells. 10:32582021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McCoach CE, Le AT, Gowan K, Jones K,
Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn
PA Jr, et al: Resistance mechanisms to targeted therapies in
ROS1+ and ALK+ non-small cell lung cancer.
Clin Cancer Res. 24:3334–3347. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mamdani H, Matosevic S, Khalid AB, Durm G
and Jalal SI: Immunotherapy in lung cancer: Current landscape and
future directions. Front Immunol. 13:8236182022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chew HY, De Lima PO, Gonzalez Cruz JL,
Banushi B, Echejoh G, Hu L, Joseph SR, Lum B, Rae J, O'Donnell JS,
et al: Endocytosis inhibition in humans to improve responses to
ADCC-mediating antibodies. Cell. 180:895–914.e27. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun J, Zhang Z, Bao S, Yan C, Hou P, Wu N,
Su J, Xu L and Zhou M: Identification of tumor immune
infiltration-associated lncRNAs for improving prognosis and
immunotherapy response of patients with non-small cell lung cancer.
J Immunother Cancer. 8:e0001102020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xie Q, Chu H, Yi J, Yu H, Gu T, Guan Y,
Liu X, Liang J, Li Y and Wang J: Identification of a prognostic
immune-related signature for small cell lung cancer. Cancer Med.
10:9115–9128. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li B, Cui Y, Diehn M and Li R: Development
and validation of an individualized immune prognostic signature in
early-stage nonsquamous non-small cell lung cancer. JAMA Oncol.
3:1529–1537. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun S, Guo W, Wang Z, Wang X, Zhang G,
Zhang H, Li R, Gao Y, Qiu B, Tan F, et al: Development and
validation of an immune-related prognostic signature in lung
adenocarcinoma. Cancer Med. 9:5960–5975. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Diao X, Guo C and Li S: Identification of
a novel anoikis-related gene signature to predict prognosis and
tumor microenvironment in lung adenocarcinoma. Thorac Cancer.
14:320–330. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang L, Zhang Z and Yu Z: Identification
of a novel glycolysis-related gene signature for predicting
metastasis and survival in patients with lung adenocarcinoma. J
Transl Med. 17:4232019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Govindan R, Ding L, Griffith M,
Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L,
Wallis J, et al: Genomic landscape of non-small cell lung cancer in
smokers and never-smokers. Cell. 150:1121–1134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi X, Kou M, Dong X, Zhai J, Liu X, Lu D,
Ni Z, Jiang J and Cai K: Integrative pan cancer analysis reveals
the importance of CFTR in lung adenocarcinoma prognosis. Genomics.
114:1102792022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ma S, Zhang L, Ren Y, Dai W, Chen T, Luo
L, Zeng J, Mi K, Lang J and Cao B: Epiregulin confers EGFR-TKI
resistance via EGFR/ErbB2 heterodimer in non-small cell lung
cancer. Oncogene. 40:2596–2609. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Umeda Y, Hasegawa Y, Otsuka M, Ariki S,
Takamiya R, Saito A, Uehara Y, Saijo H, Kuronuma K, Chiba H, et al:
Surfactant protein D inhibits activation of non-small cell lung
cancer-associated mutant EGFR and affects clinical outcomes of
patients. Oncogene. 36:6432–6445. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Peng DH, Ungewiss C, Tong P, Byers LA,
Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C, et
al: ZEB1 induces LOXL2-mediated collagen stabilization and
deposition in the extracellular matrix to drive lung cancer
invasion and metastasis. Oncogene. 36:1925–1938. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shi L, Xu Z, Yang Q, Huang Y, Gong Y, Wang
F and Ke B: IL-7-Mediated IL-7R-JAK3/STAT5 signalling pathway
contributes to chemotherapeutic sensitivity in non-small-cell lung
cancer. Cell Prolif. 52:e126992019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ke B, Wei T, Huang Y, Gong Y, Wu G, Liu J,
Chen X and Shi L: Interleukin-7 resensitizes non-small-cell lung
cancer to cisplatin via inhibition of ABCG2. Mediators Inflamm.
2019:72414182019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kumar MS, Hancock DC, Molina-Arcas M,
Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E,
Lassailly F, Matthews N, Nye E, et al: The GATA2 transcriptional
network is requisite for RAS oncogene-driven non-small cell lung
cancer. Cell. 149:642–655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Koh HM and Song DH: Prognostic role of
Rab27A and Rab27B expression in patients with non-small cell lung
carcinoma. Thorac Cancer. 10:143–149. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wu YJ, Nai AT, He GC, Xiao F, Li ZM, Tang
SY, Liu YP and Ai XH: DPYSL2 as potential diagnostic and prognostic
biomarker linked to immune infiltration in lung adenocarcinoma.
World J Surg Oncol. 19:2742021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ren Z, Hu M, Wang Z, Ge J, Zhou X, Zhang G
and Zheng H: Ferroptosis-related genes in lung adenocarcinoma:
Prognostic signature and immune, drug resistance, mutation
analysis. Front Genet. 12:6729042021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xie M, Yu X, Chu X, Xie H, Zhou J, Zhao J
and Su C: Low baseline plasma PCSK9 level is associated with good
clinical outcomes of immune checkpoint inhibitors in advanced
non-small cell lung cancer. Thorac Cancer. 13:353–360. 2022.
View Article : Google Scholar : PubMed/NCBI
|
